in pictures and a few words
What it is and why it matters
Mirogabalin is a tablet for a special kind of pain that comes from a damaged nerve. It belongs to the same family of medicines as pregabalin.
- It helps with pain after shingles
- And with pain when diabetes damages the nerves of the feet and lower legs over years
- Approved in Japan and a number of Asian countries
What kind of pain this is
Ordinary pain comes from a wound or inflammation. Here the nerve itself is damaged, and it sends pain signals on its own.
- Burning, as if the skin had been scalded
- Shooting pains, like electric shocks
- Even a bedsheet or a sleeve hurts
How it works
Ordinary painkillers are designed for inflammation and work poorly here. What helps are medicines that calm an over-excited nerve.
- A damaged nerve fires its signal at any trigger, or with none at all
- The medicine dampens wiring that has become too sensitive
What makes it special
The spot where the medicine binds comes in two kinds. One is linked to pain relief, the other to dizziness and drowsiness.
- Mirogabalin binds more precisely to the one linked to pain relief
- It stays on that one for a long time and leaves the other quickly
Pain becomes less
In patients from Asia with pain after shingles and pain from diabetes, pain fell more than in those who took tablets without the medicine.
- The higher the dose, the greater the relief
Tested in people. Tested in people: in two large studies in Asian countries.
How to read the result
A person feels more relief than the study numbers show. They count only what the medicine adds on top of a dummy pill.
- People feel better on a dummy pill too
- The goal is to make the pain bearable, not to remove it entirely
A year of treatment
In a year-long study of people with pain from diabetes, pain scores fell throughout the year.
- Most stayed until the end of the study
- Over the year, one in eight stopped taking it because of side effects
How to take it
The dose is raised gradually: drowsiness and dizziness depend on the dose and usually ease as the body gets used to it.
- The effect is judged over several weeks — each person differently
- Some are helped clearly, some not at all
Who should see a doctor first
Drowsiness and dizziness can occur — the higher the dose, the more often; medicines of this kind can also cause swelling and weight gain.
- No driving in the first weeks until it’s clear how you tolerate it
- No benefit is a reason to stop, not to put up with side effects
- Stopping abruptly is undesirable: lowering the dose is discussed with a doctor
Important. Nobody can vouch for the authenticity of tablets sold outside Japanese pharmacies.
In one sentence
Mirogabalin binds more precisely where pain relief begins and reduces this kind of pain more than a dummy pill; the dose is raised gradually, with no driving in the first weeks.
Key points
Mirogabalin (Tarlige) is a tablet for neuropathic pain from the same class as pregabalin and gabapentin, approved in Japan and several Asian countries: it binds more precisely to the part of the target responsible for pain relief and stays bound to it longer.
| Situation | How it helps | What human studies showed |
|---|---|---|
| Postherpetic neuralgia — pain after shingles | calms an over-excited nerve | 763 patients, up to 14 weeks: pain on a 0–10 scale fell more than on placebo — by 0.41, 0.47 and 0.77 points at 15, 20 and 30 mg a day, significant in all three groups [1] |
| Diabetic neuropathy and postherpetic neuralgia | pain relief rises with dose | pooled analysis of the two pivotal studies, 1587 patients (824 with diabetic neuropathic pain): 20 mg a day −0.31 points (95% CI −0.55 to −0.08), 30 mg −0.63 (95% CI −0.86 to −0.40) versus placebo [2] |
| Long-term use | in a one-year study pain scores generally declined | one-year study in diabetic neuropathic pain: pain scores declined across all 52 weeks; 172 of 214 enrolled (80.4%) reached the end [3] |
| Precision for the target | binds α2δ-1, linked to pain relief, and dissociates from it slowly, while leaving α2δ-2 (dizziness, drowsiness) quickly | — |
How it helps
What kind of pain this is
Familiar pain has a source: a wound, inflammation, a strain. The nerve reports it faithfully, and a painkiller works on the source.
Hence its recognisable oddities:
▸burning, as though the skin had been scalded; ▸electric shocks, sudden and brief; ▸numbness mixed with pain — an area that simultaneously feels nothing and hurts; ▸pain from light touch — when a sheet or a sleeve becomes unbearable.
The two commonest causes are shingles, which leaves postherpetic neuralgia behind it, and diabetes, in which the long nerves of the feet and lower legs are damaged over years.
Ordinary painkillers work poorly here: there is no inflammation for them to act on. What helps are drugs that calm an over-excited nerve — and that is where this class comes in.
The class's idea: not to mask the pain but to quieten the excited wire
In a nerve ending there are calcium channels: when calcium enters through them, transmitter substances are released and the signal travels on. In a damaged nerve this machinery is disordered — there are more channels, and the signal fires on any pretext or none.
The channel has an accessory part, the α2δ subunit. Pregabalin and gabapentin bind precisely to it and reduce the excessive release of transmitters. This is not pain relief in the usual sense but turning down over-sensitive wiring.
The drug's idea: hit the right half of the target
Here the subtlety begins. The α2δ subunit exists in two forms:
▸α2δ-1 — linked to pain relief; ▸α2δ-2 — linked to dizziness and drowsiness.
Pregabalin binds both. Hence the logical move: build a molecule that prefers the first.
Mirogabalin is designed that way, and it has a second feature more important than the preference itself: it dissociates from α2δ-1 slowly and from α2δ-2 quickly. It lingers where it is wanted and does not linger where it is a nuisance.
The comparison that fits: if a remote has two buttons under one finger — 'turn down the pain' and 'turn down consciousness' — you can make the finger thinner, press mostly the first, and rest on it longer.
What the trials showed
How to read 0.77 points properly
This is not the total relief the patient feels. What is measured is the difference between groups, and in pain trials improvement on placebo is substantial: people report less pain on a dummy too. A patient on the drug feels both their own improvement and the placebo component — and only what remains on top reaches the table.
How to take it
▸The dose is raised gradually — precisely because drowsiness and dizziness are dose-dependent and usually ease as tolerance develops. ▸Doses from the trials. In the pooled analysis, 10 mg twice daily (20 mg/day) and 15 mg twice daily (30 mg/day) gave a significant difference from placebo. ▸Expectations must be realistic. The aim of this class is to make pain bearable, not to remove it. Expecting 'it will stop hurting' leads to disappointment and to endless dose escalation. ▸The effect is judged in the individual over a few weeks: behind an average difference stand both those the drug helped distinctly and those it did not help at all.
Who should see a doctor first
| Adverse event | Placebo | 15 mg/day | 20 mg/day | 30 mg/day |
|---|---|---|---|---|
| Drowsiness | 3.8% | 10.8% | 14.5% | 19.1% |
| Dizziness | 2.7% | 5.7% | 9.1% | 13.1% |
The greatest relief and the greatest drowsiness sit at the same dose. One patient in five on 30 mg a day was drowsy, and one in eight dizzy. Discontinuations for these events were uncommon: 0.6–1.9% depending on dose in the 14-week trials. But over a year in diabetic neuropathic pain, 13.1% stopped because of adverse events — one patient in eight.
▸No driving in the first weeks, until tolerability is clear. ▸Absence of response is a reason to stop, not to endure side effects for nothing or to continue 'just in case'. ▸Abrupt withdrawal is undesirable across the class — tapering is discussed with the physician.
Bottom line
▸The same class as pregabalin, but more precise for α2δ-1 and slower to leave it. ▸Pain relief is demonstrated and rises with dose: 0.41–0.77 points out of ten against placebo. ▸In the pooled analysis 20 and 30 mg daily gave a significant result. ▸In diabetic neuropathic pain pain scores declined throughout the year of observation. ▸Available only in Japan and parts of Asia.
References
1. Kato J, et al. Mirogabalin for the management of postherpetic neuralgia: a randomized, double-blind, placebo-controlled phase 3 study in Asian patients. Pain. 2019;160(5):1175–1185. PMID 30913164
2. Kato J, et al. Safety and Efficacy of Mirogabalin for Peripheral Neuropathic Pain: Pooled Analysis of Two Pivotal Phase III Studies. Clin Ther. 2021;43(5):822–835.e16. PMID 34059327
3. Baba M, et al. Long-term safety and efficacy of mirogabalin in Asian patients with diabetic peripheral neuropathic pain. J Diabetes Investig. 2020;11(3):693–698. PMID 31722446
Caveats
The 15 mg daily dose showed no significant advantage over placebo in the pooled analysis.
Selectivity did not abolish the class's side effects. It promised less drowsiness and dizziness, but they remained and rise with dose; precision for α2δ-1 explains the molecular mechanism, but at best it shifted the ratio.
What cannot be claimed yet:
▸Superiority over pregabalin is not demonstrated. No head-to-head comparisons of adequate quality and size exist. Comparing results across separate trials is not valid — patients, scales and placebo-response levels all differ. ▸Only Asian populations were studied. All pivotal trials ran in Japan, South Korea, Taiwan, Singapore, Malaysia and Thailand. Differences in drug metabolism between populations are well known, and results cannot simply be carried over. ▸There is no FDA or EMA approval. That is no verdict on the molecule, but it does mean the drug has not passed the independent assessment of those regulators. ▸The observation horizon is one year. For pain treated over decades, that is not much. ▸Effects on function and quality of life — sleep, capacity for work, mood — were not primary endpoints; how far 0.6 points of relief changes a life does not follow from these data.
This material is for information only and does not replace a consultation with a doctor.
Key facts
- Mirogabalin (brand name Tarlige, Daiichi Sankyo) is a ligand of the α2δ subunit of voltage-dependent calcium channels — the same class as pregabalin and gabapentin; it is approved in Japan and several Asian countries.
- The α2δ subunit exists in two forms: α2δ-1 is linked to pain relief and α2δ-2 to dizziness and drowsiness; mirogabalin targets the first more precisely and stays bound to it longer.
- In the postherpetic neuralgia trial in 763 patients, the difference from the average pain reduction on placebo was 0.41, 0.47 and 0.77 points on a ten-point scale for daily doses of 15, 20 and 30 mg — all significant.
- In the pooled analysis of the two pivotal studies (1587 patients with diabetic neuropathic pain and postherpetic neuralgia), the 20 and 30 mg daily doses significantly beat placebo: −0.31 and −0.63 points.
- Drowsiness and dizziness rise with dose: at 30 mg a day 19.1% and 13.1% versus 3.8% and 2.7% on placebo; that is why the dose is raised gradually and there is no driving in the first weeks.
